

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
30 November 2000 (30.11.2000)

PCT

(10) International Publication Number
WO 00/71101 A3

(51) International Patent Classification⁷: A61K 31/00, 31/472, 31/675, 31/4725, 31/706, 31/4741, 31/473, 31/47, 31/4709, 31/185, 31/194, 31/192, A61P 43/00

(74) Agents: COTE, France et al.: Swabey Ogilvy Renault, Suite 1600, 1981 McGill College Avenue, Montreal, Québec H3A 2Y3 (CA).

(21) International Application Number: PCT/CA00/00607

(81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW.

(22) International Filing Date: 24 May 2000 (24.05.2000)

(84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

(25) Filing Language: English

Published:

— with international search report

(26) Publication Language: English

(88) Date of publication of the international search report: 6 December 2001

(30) Priority Data:

60/135,545 24 May 1999 (24.05.1999) US
60/143,123 9 July 1999 (09.07.1999) US
09/576,677 23 May 2000 (23.05.2000) US

(71) Applicants: QUEEN'S UNIVERSITY AT KINGSTON [CA/CA]: Kingston, Ontario K7L 3N6 (CA). NEUROCHEM, INC. [CA/CA]: 7220 Frederick-Banting, Suite 100, Ville St-Laurent, Québec H4S 2A1 (CA).

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(72) Inventors: SZAREK, Walter, A.: 165 Ontario Street, Suite 301, Kingston, Ontario K7L 2Y6 (CA). WEAVER, Donald, E.: 27 College View Crescent, Kingston, Ontario K7M 7J8 (CA). KONG, Xianqi: 130 Place Angora, Dollard-des-Ormeaux, Québec H9B 2G8 (CA). GUPTA, Ajay: 255 St-Louis, Pointe-Claire, Québec H9R 5L6 (CA). MIGNEAULT, David: 750 Chabrier, Apt. 7, Laval, Québec H7S 2L2 (CA).

WO 00/71101 A3

(54) Title: METHODS AND COMPOUNDS FOR INHIBITING AMYLOID DEPOSITS

(57) Abstract: Methods and compositions which are useful in the treatment of amyloidosis. In particular, methods and compositions are provided for inhibiting, preventing and treating amyloid deposition, e.g., in pancreatic islets, wherein the amyloidotic deposits are islet amyloid polypeptide (IAPP)-associated amyloid deposition or deposits. The methods of the invention involve administering to a subject a therapeutic compound which inhibits IAPP-associated amyloid deposits. Accordingly, the compositions and methods of the invention are useful for inhibiting IAPP-associated amyloidosis in disorders in which such amyloid deposition occurs, such as diabetes.

INTERNATIONAL SEARCH REPORT

International Application No
PCT/CA 00/00607

A. CLASSIFICATION OF SUBJECT MATTER					
IPC 7 A61K31/00 A61K31/472 A61K31/675 A61K31/4725 A61K31/706 A61K31/4741 A61K31/473 A61K31/47 A61K31/4709 A61K31/185 A61K31/194 A61K31/192 A61P43/00					
According to International Patent Classification (IPC) or to both national classification and IPC					
B. FIELDS SEARCHED					
Minimum documentation searched (classification system followed by classification symbols)					
IPC 7 A61K					
Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched					
Electronic data base consulted during the international search (name of data base and, where practical, search terms used)					
EPO-Internal, CHEM ABS Data, MEDLINE, BIOSIS, EMBASE					
C. DOCUMENTS CONSIDERED TO BE RELEVANT					
Category *	Citation of document, with indication, where appropriate, of the relevant passages				Relevant to claim No.
E	WO 01 03680 A (FRASER PAUL ;NEUROCHEM INC (CA); SZAREK WALTER (CA); WEAVER DONALD) 18 January 2001 (2001-01-18) abstract; claims; examples --- WO 00 64420 A (KONG XIANQI ;NEUROCHEM INC (CA); SZAREK WALTER (CA); UNIV KINGSTON) 2 November 2000 (2000-11-02) abstract page 2, line 15 -page 4, line 25 page 12, line 17 -page 16, line 13 page 22, line 21 -page 23, line 5; claims 1-11,37-53; figures; examples 6,7,9 --- -/--				1-31
E					1-31
<input checked="" type="checkbox"/> Further documents are listed in the continuation of box C. <input checked="" type="checkbox"/> Patent family members are listed in annex.					
* Special categories of cited documents : "A" document defining the general state of the art which is not considered to be of particular relevance "E" earlier document but published on or after the international filing date "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) "O" document referring to an oral disclosure, use, exhibition or other means "P" document published prior to the international filing date but later than the priority date claimed					
"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art "S" document member of the same patent family					
Date of the actual completion of the international search			Date of mailing of the international search report		
2 May 2001			25.05.01		
Name and mailing address of the ISA			Authorized officer		
European Patent Office, P.B. 5818 Patentlaan 2 NL - 2280 HV Rijswijk Tel. (+31-70) 340-2040, Tx. 31 651 epo nl, Fax: (+31-70) 340-3016			Hoff, P		

INTERNATIONAL SEARCH REPORT

International Application No
PCT/CA 00/00607

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
E	WO 00 57707 A (PROTEOTECH INC) 5 October 2000 (2000-10-05) abstract page 1, line 1 -page 2, line 9 page 3, line 4 -page 4, line 3 page 5, line 19 - line 24; claims 1,11,12,14; example 6 ---	1,6,7, 12,17, 22,31
P,X	WO 00 06133 A (NEUROCHEM INC ;UNIV KINGSTON (CA)) 10 February 2000 (2000-02-10) abstract page 2, line 8 -page 4, line 30 page 42 page 48 -page 49; claims; figures 1-4,10 ---	8-11, 27-30
X	WO 96 28187 A (KISILEVSKY ROBERT ;SZAREK WALTER (CA); UNIV KINGSTON (CA); WEAVER) 19 September 1996 (1996-09-19) the whole document, in particular page 20, lines 15-27; figure 10, compounds XXVII,XXX,XXXII ---	1-3,6-9, 12-14, 17-19, 22-24, 27,28,31
X	POWELL D S (REPRINT) ET AL: "Insulin and polyionic sulphonates modify human islet amyloid polypeptide fibril aggregation in vitro" DIABETOLOGIA, (AUG 1998) VOL. 41, SUPP. [1], PP. 656-656. PUBLISHER: SPRINGER VERLAG, 175 FIFTH AVE, NEW YORK, NY 10010. ISSN: 0012-186X., XP0000978398 RADCLIFFE INFIRM, DIABET RES LABS, OXFORD OX2 6HE, ENGLAND;UNIV OXFORD, DEPT HUMAN ANAT, OXFORD OX1 3QX, ENGLAND; UNIV TORONTO, CNDR, TORONTO, ON, CANADA; QUEENS UNIV, DEPT CHEM, KINGSTON, ON K7L 3N6, CANADA the whole document ---	1,6,7, 12,17, 22,31
X	WO 94 22437 A (UNIV KINGSTON) 13 October 1994 (1994-10-13) the whole document, in particular page 15, lines 21-33 ---	1,6,7, 12,17, 22,31
		-/-

INTERNATIONAL SEARCH REPORT

International Application No
PCT/CA 00/00607

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	US 5 164 295 A (KISILEVSKY ROBERT ET AL) 17 November 1992 (1992-11-17) abstract column 1, line 1 - line 53 column 2, line 10 - line 44 column 7, line 25 - line 41; claim 1 ---	1,6,7, 12,17, 22,31
X	WO 97 09976 A (UNIV WASHINGTON) 20 March 1997 (1997-03-20) abstract page 2, line 27 - line 34; claims 1-4 ---	8,9,27, 28
A	WO 96 37612 A (PFIZER ;CARTY MAYNARD D (US); KREUTTER DAVID K (US); SOELLER WALTE) 28 November 1996 (1996-11-28) page 1, line 1 - line 22 page 3, line 18 - line 26; claims 25-31; figures 6,7 ---	1-3,6-9, 12-14, 17-19, 22-24, 27,28,31
A	O'BRIEN T D ET AL: "HUMAN ISLET AMYLOID POLYPEPTIDE EXPRESSION IN COS-1 CELLS A MODEL OF INTRACELLULAR AMYLOIDOGENESIS" AMERICAN JOURNAL OF PATHOLOGY,US,PHILADELPHIA, PA, vol. 147, no. 3, 1 September 1995 (1995-09-01), pages 609-616, XP000590832 ISSN: 0002-9440 the whole document ---	1-3,6-9, 12-14, 17-19, 22-24, 27,28,31
X	DE 43 13 118 A (HOECHST AG) 27 October 1994 (1994-10-27) the whole document ---	10,11,29
X	GEORGIEV, V. S. ET AL: "Drug-induced modifications of the immune response. 1. Substituted 1-phenylisoquinolines" J. MED. CHEM. (1979), 22(4), 348-52 , XP000992891 the whole document, in particular compound 25 ---	10,11, 29,30
X	US 3 872 125 A (HOUЛИHAN WILLIAM J ET AL) 18 March 1975 (1975-03-18) the whole document ---	10,29
A	4,5,15, 16,20, 21,25,26	
	-/-	

INTERNATIONAL SEARCH REPORT

 International Application No
 PCT/CA 00/00607

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	EP 0 236 251 A (UNIV PASTEUR) 9 September 1987 (1987-09-09) abstract; claims 1,10,17; examples	10,29
A		4,5,15, 16,20, 21,25,26
A	BAURES, PAUL W. ET AL: "Discovering transthyretin amyloid fibril inhibitors by limited screening" BIOORG. MED. CHEM. (1998), 6(8), 1389-1401 ' XP002129747 abstract; figure 1 ---	4,5,15, 16,20, 21,25,26
A	MALMUSI L ET AL: "1,2,3,4-TETRAHYDROISOQUINOLINE AND RELATED ANALOGS OF THE PHENYLALKYLAMINE DESIGNER DRUG MDMA" MEDICINAL CHEMISTRY RESEARCH, BIRKHAEUSER, BOSTON, US, vol. 6, no. 6, 1996, pages 412-426, XP000978322 ISSN: 1054-2523 abstract; table 2 -----	10,11, 29,30

INTERNATIONAL SEARCH REPORT

International application No.
PCT/CA 00/00607

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. Claims Nos.: because they relate to subject matter not required to be searched by this Authority, namely:
Although claims 1-7,12-26 are directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.
2. Claims Nos.: because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
see FURTHER INFORMATION sheet PCT/ISA/210
3. Claims Nos.: because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

See additional sheet

1. As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

The additional search fees were accompanied by the applicant's protest.

No protest accompanied the payment of additional search fees.

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

1. Claims: 1(partially),2,3,6(partially),7(partially),8,9,12(partially),
13,14,17(partially),18,19,22(partially),23,24,27,28,31(partially)

Method for inhibiting IAPP-associated amyloid deposits with an
IAPP-inhibiting compound such as defined in claims 2-3 and composition
thereof.

2. Claims: 1(partially),4,5,6(partially),7(partially),10,11,12(partially),
15,16,17(partially),20,21,22(partially),25,26,29,30,31(partially)

Method for inhibiting IAPP-associated amyloid deposits with an
IAPP-inhibiting compound such as defined in claims 4-5 and composition
thereof

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

Continuation of Box I.2

Present claims 1,6,7,12,17,22,31 relate to a compound defined by reference to a desirable characteristic or property, namely "IAPP-inhibiting compound".

The claims cover all compounds having this characteristic or property, whereas the application provides support within the meaning of Article 6 PCT and disclosure within the meaning of Article 5 PCT for only a very limited number of such compounds. In the present case, the claims so lack support, and the application so lacks disclosure, that a meaningful search over the whole of the claimed scope is impossible. Independent of the above reasoning, the claims also lack clarity (Article 6 PCT). An attempt is made to define the compound by reference to its pharmacological profile. Again, this lack of clarity in the present case is such as to render a meaningful search over the whole of the claimed scope impossible.

Furthermore, present claims 2,4,8,10,13,15,18,20,23,25,27,29 relate to an extremely large number of possible compounds. Support within the meaning of Article 6 PCT and disclosure within the meaning of Article 5 PCT is to be found, however, for only a very small proportion of the compounds claimed. In the present case, the claims so lack support, and the application so lacks disclosure, that a meaningful search over the whole of the claimed scope is impossible.

Consequently, the search has been carried out for those parts of the claims which appear to be clear, supported and disclosed, namely those parts relating to the compounds structurally identified in FIGs 1-14, and to 1,2,3,4-tetrahydroisoquinoline derivatives, with due regard to the general idea underlying the present invention.

Claims searched completely: 3,5,9,11,14,16,19,21,24,26,28,30
Claims searched incompletely:

1-2,4,6-8,10,12,13,15,17,18,20,22,23,25,27,29,31

The applicant's attention is drawn to the fact that claims, or parts of claims, relating to inventions in respect of which no international search report has been established need not be the subject of an international preliminary examination (Rule 66.1(e) PCT). The applicant is advised that the EPO policy when acting as an International Preliminary Examining Authority is normally not to carry out a preliminary examination on matter which has not been searched. This is the case irrespective of whether or not the claims are amended following receipt of the search report or during any Chapter II procedure.

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/CA 00/00607

Patent document cited in search report		Publication date	Patent family member(s)		Publication date
WO 0103680	A	18-01-2001	NONE		

WO 0064420	A	02-11-2000	AU 4282400 A	10-11-2000	
			AU 4905000 A	12-12-2000	
			WO 0071101 A	30-11-2000	

WO 0057707	A	05-10-2000	AU 3886200 A	16-10-2000	

WO 0006133	A	10-02-2000	AU 5189499 A	21-02-2000	

WO 9628187	A	19-09-1996	US 5643562 A	01-07-1997	
			US 5972328 A	26-10-1999	
			US 5840294 A	24-11-1998	
			AU 716218 B	24-02-2000	
			AU 5097696 A	02-10-1996	
			BR 9607197 A	11-11-1997	
			CA 2213759 A	19-09-1996	
			EP 0814842 A	07-01-1998	
			JP 11501635 T	09-02-1999	
			US 5728375 A	17-03-1998	

WO 9422437	A	13-10-1994	CA 2159326 A	13-10-1994	
			CA 2159649 A	13-10-1994	
			WO 9422885 A	13-10-1994	
			EP 1060750 A	20-12-2000	
			EP 0691844 A	17-01-1996	
			EP 0691976 A	17-01-1996	
			JP 8508260 T	03-09-1996	
			US 5643562 A	01-07-1997	
			US 5972328 A	26-10-1999	
			US 5728375 A	17-03-1998	
			US 5840294 A	24-11-1998	

US 5164295	A	17-11-1992	NONE		

WO 9709976	A	20-03-1997	AU 6887996 A	01-04-1997	

WO 9637612	A	28-11-1996	US 6187991 B	13-02-2001	
			CA 2219629 A	28-11-1996	
			EP 0827540 A	11-03-1998	
			JP 10507084 T	14-07-1998	

DE 4313118	A	27-10-1994	NONE		

US 3872125	A	18-03-1975	US 3989704 A	02-11-1976	

EP 0236251	A	09-09-1987	FR 2595356 A	11-09-1987	
			WO 8705295 A	11-09-1987	
			JP 63502750 T	13-10-1988	
			US 4925943 A	15-05-1990	

